Cargando…

Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach

The rapidly spreading, highly contagious and pathogenic SARS-coronavirus 2 (SARS-CoV-2) associated Coronavirus Disease 2019 (COVID-19) has been declared as a pandemic by the World Health Organization (WHO). The novel 2019 SARS-CoV-2 enters the host cell by binding of the viral surface spike glycopro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choudhary, Shweta, Malik, Yashpal S., Tomar, Shailly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365927/ https://www.ncbi.nlm.nih.gov/pubmed/32754161 http://dx.doi.org/10.3389/fimmu.2020.01664

Ejemplares similares

Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
por: Dubey, Aakriti, et al.
Publicado: (2021)

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles
por: Chen, Catherine Z., et al.
Publicado: (2020)

In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
por: Wei, Tian-zi, et al.
Publicado: (2020)

Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study
por: Ferraz, Witor Ribeiro, et al.
Publicado: (2020)

Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing
por: Tristán-Flores, Fabiola E, et al.
Publicado: (2021)

The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
por: Ahmad, Iqrar, et al.
Publicado: (2021)

In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals
por: Şimşek, Yusuf, et al.
Publicado: (2021)

In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing
por: Afreen, Rukhsar, et al.
Publicado: (2022)

Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry
por: Zhang, Dingqi, et al.
Publicado: (2021)

Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens
por: Mahajan, Supreeti, et al.
Publicado: (2021)

Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach
por: Behera, Santosh Kumar, et al.
Publicado: (2021)

Prospects for mucosal vaccine: shutting the door on SARS-CoV-2
por: Mudgal, Rajat, et al.
Publicado: (2020)

Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library
por: Tomar, Prabhat Pratap Singh, et al.
Publicado: (2021)

Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening
por: Kirstgen, Michael, et al.
Publicado: (2021)

Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an In Silico Proteomics Approach
por: Kesarwani, Veerbhan, et al.
Publicado: (2021)

Multifunctional inhibitors of SARS-CoV-2 by MM/PBSA, essential dynamics, and molecular dynamic investigations
por: Kumar, K. Amith, et al.
Publicado: (2021)

Screening of Natural Products Inhibitors of SARS-CoV-2 Entry
por: González-Maldonado, Pamela, et al.
Publicado: (2022)

Identification of SARS-CoV-2 inhibitors through phylogenetics and drug repurposing
por: Mishra, Anamika, et al.
Publicado: (2022)

Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study
por: Eweas, Ahmad F., et al.
Publicado: (2022)

Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1
por: Yang, Jing, et al.
Publicado: (2021)

Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry
por: Palacios-Rápalo, Selvin Noé, et al.
Publicado: (2021)

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method
por: Sencanski, Milan, et al.
Publicado: (2020)

Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles
por: Hsieh, Miao-Hsi, et al.
Publicado: (2021)

Drug-Repurposing Approach To Combat Staphylococcus aureus: Biomolecular and Binding Interaction Study
por: Singh, Vishakha, et al.
Publicado: (2022)

Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design
por: Meyer-Almes, Franz-Josef
Publicado: (2020)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry
por: Tong, Qiyu, et al.
Publicado: (2023)

In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus
por: Tietcheu Galani, Borris Rosnay, et al.
Publicado: (2021)

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
por: Rodon, Jordi, et al.
Publicado: (2021)

Identification of potent small molecule inhibitors of SARS-CoV-2 entry
por: Mediouni, Sonia, et al.
Publicado: (2022)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
por: Dittmar, Mark, et al.
Publicado: (2021)

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor
por: Han, Dong P., et al.
Publicado: (2006)

In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
por: Maffucci, Irene, et al.
Publicado: (2020)

Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential
por: Ayoup, Mohammed Salah, et al.
Publicado: (2023)

In Silico Drug Repurposing for Anti-Inflammatory Therapy: Virtual Search for Dual Inhibitors of Caspase-1 and TNF-Alpha
por: Speck-Planche, Alejandro, et al.
Publicado: (2021)

Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses
por: Cao, Yingying, et al.
Publicado: (2021)

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
por: Zhao, Hanjun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_93b3lrpa7df1o7arq4nt8ipto4